Regulatory milestones

ALK-Abello A/S (CSE:ALK-B) was down DKK3 to DKK416 last week after FDA accepted for review a BLA from partner Merck & Co. Inc. (NYSE:MRK) for Ragweed Allergy Immunotherapy Tablet (AIT) in adults with ragweed-induced allergic rhinitis. The pharma said it expects a decision in 1H14.